Akebia Therapeutics (AKBA) Misses Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
Akebia Therapeutics Reports First Quarter 2022 Financial Results and Business Update
May 9, 2022 4:05 PM EDTNet Auryxia® (ferric citrate) product revenue of $41.4M, a 36% increase over Q1 20212022 Net Auryxia product revenue guidance of $165 - $170MOutlines refined strategic focus to deliver shareholder valueAkebia to host conference call on Monday, May 9 at 4:30 p.m. ET
CAMBRIDGE, Mass., May 9, 2022 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by... More
